2-[((2',6'-DICHLORO-4'-HYDROXY)PHENYL)AMINO]BENZENEACETIC ACID Chemical Properties

Melting point:

178-185°C dec.

Boiling point:

432.7±45.0 °C(Predicted)

Density 

1.520±0.06 g/cm3(Predicted)

Flash point:

2℃

storage temp. 

-20°C

solubility 

Soluble in DMSO, ethanol or methanol

pka

4.17±0.10(Predicted)

form 

Solid

color 

White to off-white

BRN 

4198042

Stability:

Light Sensitive

Safety Information

Hazard Codes 

T,N,Xn,F

Risk Statements 

25-37/38-41-50/53-36-20/21/22-11

Safety Statements 

26-39-45-60-61-36/37-16

RIDADR 

UN 2811 6.1/PG 3

WGK Germany 

3

RTECS 

AG6542800

HazardClass 

6.1

MSDS

• Language:English Provider:SigmaAldrich

2-[((2',6'-DICHLORO-4'-HYDROXY)PHENYL)AMINO]BENZENEACETIC ACID Usage And Synthesis

Description

4-hydroxy Diclofenac is a CYP2C9 metabolite of the NSAID diclofenac . By inhibiting COX and subsequently suppressing PGE₂ synthesis, it demonstrates anti-inflammatory and analgesic properties.

Chemical Properties

Light Violet Solid

Uses

A metabolite of Diclofenac, a nonsteroidal anti-inflammatory compound and cyclooxygenase (COX) inhibitor

Uses

A Cytochrome P450 2C9 (CYP2C9) metabolite of diclofenac

Uses

A metabolite of Diclofenac, a nonsteroidal inflammatory compound and cyclooxygenase (COX) inhibitor.

Definition

ChEBI: An monocarboxylic acid that is the 4'-hydroxylated metabolite of diclofenac.

General Description

4′-Hydroxydiclofenac is one of the metabolites of diclofenac, a nonsteroidal anti-inflammatory drug (NSAID) used in human and veterinary medicine.

References

[1] R J SAWCHUK. Analysis of diclofenac and four of its metabolites in human urine by HPLC.[J]. Pharmaceutical Research, 1995, 12 5: 756-762. DOI: 10.1023/a:1016276012891
[2] ü. YA?AR. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro[J]. European Journal of Clinical Pharmacology, 2001, 57 1: 729-735. DOI: 10.1007/s00228-001-0376-7
[3] R YAMAZAKI. Hydrolytic activity is essential for aceclofenac to inhibit cyclooxygenase in rheumatoid synovial cells.[J]. Journal of Pharmacology and Experimental Therapeutics, 1999, 289 2: 676-681.
[4] FENG ZHANG. Inhibition of drug-metabolizing enzymes by Jingyin granules: implications of herb–drug interactions in antiviral therapy[J]. Acta Pharmacologica Sinica, 2021, 43 4: 1072-1081. DOI: 10.1038/s41401-021-00697-2

2-[((2',6'-DICHLORO-4'-HYDROXY)PHENYL)AMINO]BENZENEACETIC ACID(64118-84-9)Related Product Information

• 1-(2,6-Dichlorophenyl)-2-hydroindole
• 2,6-DICHLORODIPHENYLAMINE
• 2-(2,6-Dichloroanilino) benzaldehyde
• 2-[(2,6-dichlorophenyl)amino]benzoicacid
• Oxindole
• Diclofenac sodium
• (2-(2,6-DICHLOROANILINO)PHENYL) METHANOL
• 2-(2-Bromo-6-chlorophenyl)amino)-phenylacetic acid sodium salt 95%
• Diclofenac Impurity 7
• Diclofenac Impurity 16
• Phenylacetic acid
• 1-(2,6-Dichlorophenyl)-2-indolinone
• 2-[((2',6'-DICHLORO-4'-HYDROXY)PHENYL)AMINO]BENZENEACETIC ACID
• 4-Amino-3-chlorophenol hydrochloride
• 2-ANILINOPHENYLACETIC ACID
• 4-HYDROXY-2'-METHYLDIPHENYLAMINE
• 4'-Hydroxy diclofenac-d4
• (2-(2,6-Dichloro-4-hydroxyanilino)-5-hydroxyphenyl)acetic acid